M&T Bank Corp lifted its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 4.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 88,682 shares of the medical instruments supplier’s stock after purchasing an additional 3,651 shares during the quarter. M&T Bank Corp’s holdings in Becton Dickinson and were worth $22,350,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Comerica Securities Inc. increased its position in Becton Dickinson and by 31.2% in the 4th quarter. Comerica Securities Inc. now owns 2,742 shares of the medical instruments supplier’s stock valued at $618,000 after acquiring an additional 652 shares during the period. Dimensional Fund Advisors LP increased its position in Becton Dickinson and by 10.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 525,300 shares of the medical instruments supplier’s stock valued at $118,354,000 after acquiring an additional 49,738 shares during the period. Geode Capital Management LLC increased its position in Becton Dickinson and by 7.5% in the 4th quarter. Geode Capital Management LLC now owns 3,208,583 shares of the medical instruments supplier’s stock valued at $721,582,000 after acquiring an additional 223,215 shares during the period. InterOcean Capital LLC acquired a new stake in Becton Dickinson and in the 1st quarter valued at approximately $204,000. Finally, Dearborn Partners LLC increased its position in Becton Dickinson and by 1.1% in the 1st quarter. Dearborn Partners LLC now owns 178,059 shares of the medical instruments supplier’s stock valued at $44,467,000 after acquiring an additional 1,916 shares during the period. 84.11% of the stock is currently owned by institutional investors.
BDX has been the topic of several research analyst reports. KeyCorp reiterated an “overweight” rating and set a $262.00 price target (down from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. BMO Capital Markets lowered their price target on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a research report on Friday, May 10th. Piper Jaffray Companies lowered their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Co lowered their price target on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a research report on Monday, May 13th. Finally, Raymond James lifted their price target on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research report on Friday, June 28th. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $264.27.
Shares of BDX traded up $5.52 during trading hours on Wednesday, hitting $253.55. 532,244 shares of the company were exchanged, compared to its average volume of 961,386. The company has a market capitalization of $66.96 billion, a PE ratio of 23.03, a PEG ratio of 1.84 and a beta of 1.13. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67. The firm has a fifty day simple moving average of $251.21 and a 200-day simple moving average of $244.88. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $265.87.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping the consensus estimate of $3.05 by $0.03. The business had revenue of $4.35 billion during the quarter, compared to analyst estimates of $4.37 billion. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The company’s revenue was up 1.7% compared to the same quarter last year. During the same period last year, the company posted $2.91 EPS. Sell-side analysts expect that Becton Dickinson and Co will post 11.68 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s dividend payout ratio is presently 27.97%.
In other news, EVP Simon D. Campion sold 2,903 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total value of $687,836.82. Following the completion of the sale, the executive vice president now owns 9,408 shares of the company’s stock, valued at $2,229,131.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Patrick Kaltenbach sold 191 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $241.03, for a total value of $46,036.73. Following the completion of the sale, the executive vice president now directly owns 19,072 shares of the company’s stock, valued at approximately $4,596,924.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,169 shares of company stock valued at $1,996,663. Corporate insiders own 0.12% of the company’s stock.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: Hedge Funds – Risk or Reward?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.